The Clinical Challenge You Face Every Day
Standard biomarker tests leave critical questions unanswered, forcing difficult treatment decisions with incomplete information.
PD-L1 Positive, But Will They Respond?
Up to 50% of PD-L1+ patients don't respond to checkpoint inhibitors. Expression doesn't guarantee the pathway is functional.
PD-L1 Negative, Missing Responders?
Some PD-L1- patients do respond. Are you missing treatment opportunities by relying on expression alone?
Toxicity Without Benefit
Immunotherapy side effects are significant. Patients deserve to know if they're likely to benefit before exposure.
Measure What Actually Matters: Pathway Engagement
Our FLIM-FRET technology measures whether checkpoint proteins are physically binding to their targets - not just whether they're present. This is the difference between seeing a lock and knowing if a key is turning it.
- ✓ iFRET - Measures actual PD-1/PD-L1 engagement at the cellular level
- ✓ Same FFPE tissue - Works with your existing diagnostic samples
- ✓ Quantitative results - Clear threshold for treatment decisions
- ✓ 42% reclassification - Changes clinical decision for nearly half of patients
Expression Testing
Engagement Testing
Same patients, same tissue, same target - different predictive power
Clinical Evidence
Peer-reviewed studies demonstrating functional biomarkers outperform expression testing.
PD-1/PD-L1 Engagement in Lung Cancer
188 patients treated with pembrolizumab or nivolumab. High iFRET patients survived 3× longer than low iFRET patients.
PD-1/PD-L1 Engagement in Melanoma
97 melanoma patients demonstrated similar predictive power, with functional engagement outperforming standard PD-L1 testing.
Dual Checkpoint Engagement
Combined CTLA-4/CD80 + PD-1/PD-L1 measurement identifies patients with even greater precision for combination therapy.
PKB/Akt Activation in ccRCC
Demonstrates functional biomarkers work beyond immunotherapy - measuring protein activation states predicts outcomes where expression fails.
Simple Integration with Your Practice
No new biopsy required. Works with your existing diagnostic workflow.
Submit FFPE Sample
Use existing diagnostic tissue from your pathology archive
FLIM-FRET Analysis
Quantitative measurement of checkpoint engagement levels
Clear Report
High/Low engagement status with clinical context
Informed Decision
Select treatment based on functional pathway status
Ready to Learn More?
Get clinical information, discuss patient cases, or explore partnership opportunities for your institution.